This article is more than 5 years old. Information may no longer be current.

Carl Zeiss Meditec receives FDA clearance for 4.0 software version of Cirrus HD-OCT

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

DUBLIN, Calif. — A new suite of optical coherence tomography software applications for the 4.0 version of Carl Zeiss Meditec's Cirrus HD-OCT platform have been cleared for commercial distribution by the U.S. Food and Drug Administration, the company announced in a press release.

The Cirrus HD-OCT 4.0 is indicated for in vivo viewing, axial cross-sectional, and three-dimensional imaging and measurement of anterior and posterior ocular structures.

For assessing and managing glaucoma, the 4.0 version now offers a retinal nerve fiber layer normative database and imaging of the anterior segment, as well as guided progression analysis to identify statistically significant changes in RNFL thickness.

New enhancements for the management of retinal disease include macular change analysis for mapping changes in macular thickness, a fovea finder to identify the center of the fovea, as well as macular thickness normative data to identify retinal disease based on age-matched data comparisons.

The new 4.0 software is DICOM compatible for use with Carl Zeiss Meditec's connectivity solutions, including VISUPAC Star and EMR platforms, the release said.